PharmAthene
Biotechnology - Annapolis, Maryland, United States
PharmAthene Employees
Timothy Roesing
Past VP of Manufacturing, Supply, Process Sciences, IT and Facilities
PharmAthene Details
PharmAthene, Inc. (NYSE MKT: PIP), formed in March 2001, is pursuing its mission to advance the Nation's health security by developing novel medical solutions that utilize cutting-edge biotechnology to offer improvements in safety, efficacy and cost-effectiveness over current therapies. The Company's strategy focuses on acquiring and developing new, best-in-class products and technologies identified by the United States and other governments as urgent procurement priorities. Since its inception in 2001, PharmAthene has obtained non-dilutive U.S. government funding commitments in excess of $600 million for the development of its portfolio products. PharmAthene's portfolio currently includes the following product candidates: • SparVax® - a next generation recombinant protective antigen (rPA) anthrax vaccine • Recombinant BChE - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
PharmAthene Technologies
Email Providers
Outlook
Domain Name Services
DNS Made Easy
CMS
Drupal
Hosting
DigitalOcean
Search Marketing
Adobe Marketing Cloud